Shidong Xu

机构：Hunan Cancer Hospital · ORCID：0009-0009-0675-910X

发表论文 25 篇 · 总被引 506 次 · h-index 12

代表论文

• Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial (2024 · The Lancet Respiratory Medicine · 被引 122)
• Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study. (2023 · Journal of Clinical Oncology · 被引 89)
• Long Non-coding RNA JHDM1D-AS1 Interacts with DHX15 Protein to Enhance Non-Small-Cell Lung Cancer Growth and Metastasis (2019 · Molecular Therapy — Nucleic Acids · 被引 52)
• Ran GTPase Induces EMT and Enhances Invasion in Non-Small Cell Lung Cancer Cells Through Activation of PI3K-AKT Pathway (2014 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 被引 34)
• Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway (2017 · Cellular Physiology and Biochemistry · 被引 29)
• PIGF and Flt-1 on the surface of macrophages induces the production of TGF-β1 by polarized tumor-associated macrophages to promote lung cancer angiogenesis (2021 · European Journal of Pharmacology · 被引 26)